ROBOSENSE
21.4.2021 20:02:15 CEST | Business Wire | Press release
RoboSense (https://www.robosense.ai/ ), the leading smart LiDAR sensor provider announced a strategic partnership with Banma Network Technology, an intelligent automobile operating system and solution provider that cooperated with Alibaba Group and SAIC Motor, and AutoX, China's most advanced self-driving AI platform, to build a high-level autonomous driving platform for intelligent vehicles through in-depth cooperation in the 3D LiDAR sensor, AI algorithm, and intelligent automobile operating system, and create an advanced smart cockpit based on human-machine co-driving.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005523/en/
The cooperation will promote the integration of smart cockpits with autonomous driving systems through the fusion of hardware, software, and AI capabilities. RoboSense will provide the robust LiDAR sensor solution that not only meets the need for high-level autonomous driving systems, but also for Banma's advanced intelligent cockpit systems. RoboSense LiDAR provides accurate environmental perception data for the AutoX autonomous driving system "AI driver", and empowers the safety of Banma's intelligent automobile operating system.
In January 2021, RoboSense and Banma jointly established the Intelligent Perception Innovation Center. Three months later, the two parties formed a mass-production-ready solution based on the intelligent automobile operating system and automotive-grade solid-state RS-LiDAR-M1, which meets the requirements of both autonomous passenger cars and the RoboTaxi.
The Executive President and Co-Founder of RoboSense, Mark Qiu said, " With three parties' efforts on the integration of intelligent cockpit system, perception system, and AI autonomous driving solution, we are able to provide a new generation of intelligent vehicle solutions with more potential values to OEMs and other customers."
The CIO of Banma, Qiang Xu said, " Intelligent interaction, intelligent service, and intelligent driving are the three basic aspects of smart driving cars. At present, smart cockpits and autonomous driving are gradually merging with each other. In terms of hardware, we provide RoboSense with system-level support to ensure its perception power is fully utilized. As for the algorithm, we provide AutoX with a rich toolchain, cloud and end service system to create a sustainable and efficient ecological collaboration system. "
The Founder and CEO of AutoX, Jianxiong Xiao said, "With the fully driverless RoboTaxi is becoming a reality in China, passengers will have more free time in the car. More intelligent services and interactions with the car are needed for a smart and enjoyable travel experience. A complete product ecosystem formed by three parties will create a safe and enjoyable autonomous driving solution. "
About RoboSense
RoboSense is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to possess outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability more superior to humans. https://www.robosense.ai/
About Banma
Banma provides an intelligent automobile operating system, intelligent automobile solutions as well as digital transportation solutions for both automotive and transportation industries. Powered by self-developed AliOS, Banma Automobile Solutions currently have collaborated with more than 1 million vehicles. In the future, Banma will promote transportation digitalization by providing man-machine co-driving and vehicle-road collaboration. https://www.ebanma.com
About AutoX
AutoX is the market leader for RoboTaxi in China. AutoX is the only company operating fully driverless RoboTaxi fleet on public roads in China without safety drivers. The company’s self-driving platform is capable of handling the densest and most dynamic traffic conditions in urban cities around the world. AutoX is the world's second permit holder for California DMV’s completely driverless RoboTaxi permit. https://www.autox.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005523/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom